New drug ARGX-109 tested for safety in first human trial
NCT ID NCT06799416
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 1 trial tested a single dose of ARGX-109 in 40 healthy adults to see if it is safe and how the body processes it. Participants were randomly assigned to receive either the drug or a placebo. The study lasted about 20 weeks and focused on side effects and drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ARGX-109
- What this could lead to
- If successful, this could pave the way for testing ARGX-109 in people with diseases linked to inflammation.
- What could go wrong
- This is an early, small study in healthy people, so it cannot show if ARGX-109 works for any disease. Side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Altasciences - Montreal - Phase I unit
Mount Royal, Quebec, H3P 3P1, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can eye movements reveal the Brain's visual priorities?
- A new eye on the brain: could this tracer unlock Addiction's secrets?
- First look: can a new drug candidate pass early safety tests in humans?
- A painless, contact-free vibration sensor may detect hidden heart and lung problems
- Can a Two-Pathway pill improve ED treatment? a new trial puts the combo to the test
- Could a common drug shield the brain from Alzheimer's?